STOCK TITAN
  1. Home
  2. News
  3. AIMD

Ainos, Inc. - AIMD STOCK NEWS

Welcome to our dedicated page for Ainos news (Ticker: AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.

Ainos, Inc. (NASDAQ: AIMD) is a diversified healthcare company headquartered in San Diego, California, specializing in developing innovative medical technologies for point-of-care testing (POCT), low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine. The company's flagship product is VELDONA®, a low-dose oral interferon-alpha formulation aimed at enhancing immune responses against a range of diseases. Ainos' VELDONA® has shown promise in treating human disease indications such as influenza, hepatitis C, thrombocytopenia, as well as HIV-related oral warts and Behçet's disease, both of which have received Orphan Drug Designation by the U.S. FDA.

Ainos recently announced the completion of manufacturing a GMP Clinical Batch of VELDONA® in collaboration with its contract manufacturer, Swiss Pharmaceutical Co., Ltd. (Taiwan). This milestone validates Ainos' capabilities in delivering high-quality, cost-effective therapeutics and advances the company's key programs.

In addition to human therapeutics, Ainos is making strides in animal health. The company has initiated clinical trials for a new VELDONA®-based drug aimed at treating feline chronic gingivostomatitis, a serious and chronic painful oral disease. This study builds upon VELDONA®'s extensive history in animal health, demonstrating its therapeutic potential across various animal species.

Ainos is also pioneering AI-powered POCTs through its AI Nose technology platform. The company's lead POCT candidate, Ainos Flora, is designed to be a telehealth-friendly solution for women's health and common sexually transmitted infections (STIs). Furthermore, Ainos has initiated a co-development program with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co. to create a volatile organic compound (VOC) sensing platform. This technology aims to revolutionize applications in telehealth, automotive, industrial, and environmental safety, expanding Ainos' market reach.

Financially, Ainos has secured significant growth capital, including a $9 million convertible note from an existing shareholder. This funding will propel the company's initiatives in scaling up VELDONA® and advancing its AI Nose technology.

With nearly four decades of dedication to healthcare innovation, Ainos continues to push the boundaries of medical science, striving to deliver effective, safe, and high-quality treatments for both humans and animals. Investors and stakeholders are encouraged to follow Ainos on social media platforms like X (formerly Twitter) and LinkedIn for the latest updates and developments.

News

Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms

Rhea-AI Summary
Ainos, Inc. has submitted a complete response to the U.S. FDA for a Phase II trial of its low-dose oral interferon-alpha formulation, VELDONA, intended for the treatment of mild COVID-19 symptoms. The company's Phase II trial is expected to involve a multicenter, parallel, randomized study conducted in Taiwan during the third quarter of 2024. Ainos has successfully addressed the deficiencies identified by the FDA, accelerating the timeline for its clinical trials. The updated Chemistry, Manufacturing, and Controls information indicates that the stability of VELDONA can exceed the minimum shelf life of biologicals. Ainos plans to submit additional IND applications for the treatment of oral warts in HIV-seropositive patients and Sjögren's syndrome. The company aims to expand its VELDONA platform for the treatment of other viral infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags
clinical trial covid-19
-
News

Ainos Announces $1.75 Million Follow-On Funding

Rhea-AI Summary
Ainos, Inc. (NASDAQ:AIMD) has announced a $1.75 million follow-on funding from Lind Global Fund II LP, with plans to use the proceeds for VELDONA IND preparation and AI Nose VOC platform development. The funding is in the form of an amendment to a Senior Secured Convertible Promissory Note, with the Investor being granted five-year warrants equal to 75% of the funded amount at an initial exercise price of $2.16 per share of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.34%
Tags
none
-
News

Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary
Ainos, Inc. (NASDAQ: AIMD, AIMDW) regained compliance with NASDAQ's minimum bid price requirement after its common stock maintained a closing bid price of $1.00 or more for at least 10 consecutive business days, following a previous non-compliance notice on January 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
none
News

Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell

Rhea-AI Summary
Ainos, Inc. (NASDAQ: AIMD, AIMDW) announces collaboration with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co. to develop AI Nose technology for mass production readiness targeted for 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
clinical trial AI
-
News

Ainos, Inc. Announces Stock Consolidation

Rhea-AI Summary
Ainos, Inc. (NASDAQ: AIMD, AIMDW) announces a consolidation (reverse stock split) of its outstanding shares of common stock, effective December 14, 2023. The new shares of common stock will trade under a new CUSIP number, with the ticker symbol AIMD remaining unchanged. The number of outstanding common shares will be approximately 4,677,898 shares, with no fractional shares issued. Holders of fractional shares will be paid out in cash. Instructions for exchanging existing stock certificates or receiving cash proceeds will be provided by the Company's transfer agent, Equiniti Trust Company, LLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
none
-
News

Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical

Rhea-AI Summary
Ainos, Inc. (AIMD, AIMDW) collaborates with Swiss Pharmaceutical Co., Ltd. to complete the manufacturing of a GMP Clinical Batch of VELDONA® investigational new drugs. Ainos intends to submit Investigational New Drug Applications to the U.S. FDA for multiple candidates including HIV Oral Warts Orphan Drug, Sjogren's Syndrome, the Common Cold, and COVID-19 during the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
News

Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Rhea-AI Summary
Ainos, Inc. (AIMD, AIMDW) announced positive top-line data from three clinical studies for its VELDONA low-dose oral interferon formulation as a potential treatment for oral warts in HIV-seropositive patients. The results partially fulfill hypotheses, demonstrating the formulation's superior efficacy compared to a placebo. Ainos plans to pursue a pre-IND meeting with the U.S. FDA ahead of planned Phase III clinical studies for the drug candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
clinical trial
-
News

Ainos Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Ainos, Inc. (NASDAQ: AIMD, AIMDW) announced its Q3 2023 financial results, showing a transition away from COVID-19 test kits and focusing on VELDONA® Pet cytoprotein supplements. The company also reported decreased revenues but expects a boost in Q4 from VELDONA® Pet sales. The announcement highlighted a decrease in R&D expenses and a recent $3 million private placement to fund its business strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
earnings
-
News

Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA

Rhea-AI Summary
Ainos and SIDSCO will collaborate to develop new animal drugs based on Ainos' VELDONA® low-dose oral interferon. A clinical study will be conducted to investigate VELDONA®'s efficacy for the treatment of feline chronic gingivostomatitis (FCGS) via oral mucosal administration. Ainos aims to expand its product line into the global pet care market through this partnership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.54%
Tags
clinical trial
News

Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement

Rhea-AI Summary
Ainos, Inc. announces $10 million private placement with Lind Global Fund II LP. Initial conversion price set at $1.50 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.69%
Tags
none

FAQ

What is the current stock price of Ainos (AIMD)?

The current stock price of Ainos (AIMD) is $0.4511 as of December 20, 2024.

What is the market cap of Ainos (AIMD)?

The market cap of Ainos (AIMD) is approximately 6.5M.

What does Ainos, Inc. specialize in?

Ainos specializes in developing innovative medical technologies, including point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine.

What is VELDONA®?

VELDONA® is Ainos' low-dose oral interferon-alpha formulation designed to enhance immune responses against various diseases in humans and animals.

What recent milestones has Ainos achieved?

Ainos has completed manufacturing a GMP Clinical Batch of VELDONA® and initiated clinical trials for treating feline chronic gingivostomatitis with a new VELDONA®-based drug.

What are Ainos' key products?

Ainos' key products include VELDONA® clinical-stage human therapeutics, VELDONA® Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by the AI Nose technology platform.

Who are Ainos' strategic partners?

Ainos has strategic partnerships with Swiss Pharmaceutical Co., Ltd. for manufacturing and with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co. for developing VOC sensing technology.

What financial steps has Ainos recently taken?

Ainos has secured $9 million in growth capital through a convertible note financing to scale up its VELDONA® and AI Nose initiatives.

What is the AI Nose platform?

The AI Nose platform is Ainos' AI-powered technology for POCTs and VOC sensing, with potential applications in telehealth, automotive, industrial, and environmental safety.

What is Ainos Flora?

Ainos Flora is a telehealth-friendly point-of-care test for women's health and certain common sexually transmitted infections, powered by Ainos' AI Nose technology.

What is the significance of VELDONA® in animal health?

VELDONA® has a long history in animal health, initially approved in 1985 for treating feline leukemia and canine parvovirus, and is now being explored for treating feline chronic gingivostomatitis.

How can investors stay updated on Ainos' developments?

Investors can follow Ainos on X (formerly Twitter) and LinkedIn for the latest updates and company news.

Stock AIMD logo
Ainos, Inc.

Nasdaq:AIMD

AIMD Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

AIMD Stock Data

6.53M
4.09M
70.46%
1.34%
0.82%
Medical Devices
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO